Company intelligence / Profile preview

SignPost Cancer Dx

Kingston, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

SignPost Cancer Dx is developing BreastDefense, a molecular diagnostic test for invasive breast cancer, with reported accuracy rates of 98.5% to 99%. The test aims to detect all major subtypes of invasive breast cancer from stages 1 to 4.

Therapeutic areas: Oncology
Modalities: Molecular diagnostics
Industry: Molecular Diagnostics

Partnerships

Newchip accelerator programDynacare (a subsidiary of LabCorp)

Beyond the preview

Go deeper on SignPost Cancer Dx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SignPost Cancer Dx.

Explore the full profile